Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01991860 · ClinicalTrials.gov registry record · Phase 3
US Phase III Study of APD421 in PONV
A Phase 3 study of PONV, sponsored by Acacia Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 364
- Enrollment target
- 1
- Study location
NCT01991860 is a Phase 3 study of PONV that has completed, run by Acacia Pharma. The registered enrollment target is 364 participants, below the 427-participant average among 3 other PONV trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01991860, a Phase 3 study of PONV, has completed, sponsored by Acacia Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 364 participants
- Enrollment target
- 1
- Study location
Study Summary
A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG APD421- Amisulpride for IV injection
Study Locations (1)
North Carolina
- Duke - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01991860
The ClinicalTrials.gov registry entry for NCT01991860 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 427-participant average among 3 other PONV trials with a reported enrollment target (15% lower). The listed sponsor is Acacia Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PONV appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01991860 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01991860 about?
NCT01991860 is a clinical study titled "US Phase III Study of APD421 in PONV". A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
What is the current status of trial NCT01991860?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 364 participants. The study started on 2013-08. Estimated completion is 2014-01.
What conditions does trial NCT01991860 study?
This clinical trial studies the following conditions: PONV.
What interventions are being tested in trial NCT01991860?
The interventions under investigation include: Placebo (DRUG), APD421- Amisulpride for IV injection (DRUG).
Who is sponsoring clinical trial NCT01991860?
This trial is sponsored by Acacia Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01991860 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PONV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.